Medtronic Ends Insulin-Pen Deal Dispute With Device’s Ex-Owners

Litigation over Medtronic Plc’s alleged scheme to avoid $100 million in deal payments by sabotaging sales of a reusable insulin pen ended with an anticlimax Monday.

The order formally dismissing the lawsuit followed three days after the biotech giant and ex-investors in Companion Medical Inc.—which developed the diabetes device before its sale to Medtronic—submitted a joint filing dropping the case. Rick Meyer, an attorney for the former shareholders, told Bloomberg Law via email Monday that the dispute had been “amicably resolved.”

The legal filings didn’t disclose any settlement terms, which only have to be made public in cases such as ...